Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Exclusion Criteria

• •Subjects may not be receiving any other investigational agents
• •\- No history of prior malignancy, except for non-melanoma skin cancer
• •Any positive ANA titer above 1:160, even in an asymptomatic individual. Note:
• •Weakly positive ANA defined as ANA titers up to 1:160 maximum (≤ 1:160) will be acceptable in an asymptomatic individual who is otherwise eligible for the study.
• •Known Hepatitis B on immunomodulators (i.e. interferon)
• •Known Hepatitis C on immunomodulators (i.e. interferon)
• •No prior vaccine therapy
• •Patients may not be receiving any steroids or other anti-immune therapy at the time of registration.
• •Subjects must not be more than 24 weeks from standard of care treatment for their particular stage of disease
• •Subjects must not have post-obstructive pneumonia or other serious infection at the time of registration or other serious underlying medical condition that would impair the ability of the subjects to receive protocol treatment
• •Prior resection of lung cancer is allowed, if at least five years have elapsed between previous resection and registration
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Pregnant women are excluded from this study. Women of childbearing potential must have a negative pregnancy test
• •Subjects with immune deficiency are not expected to respond to the vaccine. Therefore, known HIV-positive patients are excluded from the study
• •Subjects with a history of known autoimmune disease are excluded from this study